In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text] Nephrology: [Formula: see text].